Eric A Miller1, Paul F Pinsky2, Robert E Schoen3, Philip C Prorok2, Timothy R Church4. 1. National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA. Electronic address: eric.miller2@nih.gov. 2. National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA. 3. University of Pittsburgh, Department of Medicine and Epidemiology, Pittsburgh, PA, USA. 4. University of Minnesota, School of Public Health, Minneapolis, MN, USA.
Abstract
BACKGROUND:Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of 12 years. Whether the benefit is sustained over the long term and remains so in both sexes and all age groups is uncertain. We report long-term results after an additional 5 years of follow-up. METHODS:Participants in the PLCO trial were recruited from the general population in the catchment areas of ten screening centres across the USA, without previous diagnosis of a prostate, lung, colorectal, or ovarian cancer or current cancer treatment. From 1993 to 2001, participants aged 55-74 years were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years or 5 years. Randomisation was done within blocks and stratified by centre, age, and sex. The primary endpoint was cause-specific mortality and secondary endpoints included incidence and tumour staging; cause of death was determined without knowledge of study arm. In this analysis, we assessed incidence and mortality rates overall, by time-period, and by combinations of sex, age at baseline (55-64 years/65-74 years), location (distal/proximal), and stage, on an intent-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00002540. FINDINGS: After a median follow-up of 15·8 years (IQR 13·2-18·0) for incidence and 16·8 years (14·4-18·9) for mortality, the incidence of colorectal cancer was significantly lower in the intervention arm (1461 cases; 12·55 per 10 000 person-years) than with usual care (1761 cases; 15·33 per 10 000 person-years; relative risk [RR] 0·82, 95% CI 0·76-0·88). Similarly, mortality was lower in the intervention arm (417 deaths; 3·37 per 10 000 person-years) than the usual care arm (549; 4·48 per 10 000 person-years; RR 0·75, 95% CI 0·66-0·85). The reduction in mortality was limited to the distal colon, with no significant effect in the proximal colon. Reductions in incidence were significantly larger in men than women (pinteraction=0·04) and reductions in mortality were significantly larger in the older age group (65-74 years vs 55-64 years at baseline; pinteraction=0·01). INTERPRETATION: Reductions in colorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the long term. Differences by sex and age should be examined in other ongoing trials of colorectal cancer screening to help clarify if different screening strategies would achieve greater risk reduction. FUNDING: Extended follow-up was funded under NIH contract HHSN261201600007I.
RCT Entities:
BACKGROUND: Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of 12 years. Whether the benefit is sustained over the long term and remains so in both sexes and all age groups is uncertain. We report long-term results after an additional 5 years of follow-up. METHODS:Participants in the PLCO trial were recruited from the general population in the catchment areas of ten screening centres across the USA, without previous diagnosis of a prostate, lung, colorectal, or ovarian cancer or current cancer treatment. From 1993 to 2001, participants aged 55-74 years were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years or 5 years. Randomisation was done within blocks and stratified by centre, age, and sex. The primary endpoint was cause-specific mortality and secondary endpoints included incidence and tumour staging; cause of death was determined without knowledge of study arm. In this analysis, we assessed incidence and mortality rates overall, by time-period, and by combinations of sex, age at baseline (55-64 years/65-74 years), location (distal/proximal), and stage, on an intent-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00002540. FINDINGS: After a median follow-up of 15·8 years (IQR 13·2-18·0) for incidence and 16·8 years (14·4-18·9) for mortality, the incidence of colorectal cancer was significantly lower in the intervention arm (1461 cases; 12·55 per 10 000 person-years) than with usual care (1761 cases; 15·33 per 10 000 person-years; relative risk [RR] 0·82, 95% CI 0·76-0·88). Similarly, mortality was lower in the intervention arm (417 deaths; 3·37 per 10 000 person-years) than the usual care arm (549; 4·48 per 10 000 person-years; RR 0·75, 95% CI 0·66-0·85). The reduction in mortality was limited to the distal colon, with no significant effect in the proximal colon. Reductions in incidence were significantly larger in men than women (pinteraction=0·04) and reductions in mortality were significantly larger in the older age group (65-74 years vs 55-64 years at baseline; pinteraction=0·01). INTERPRETATION: Reductions in colorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the long term. Differences by sex and age should be examined in other ongoing trials of colorectal cancer screening to help clarify if different screening strategies would achieve greater risk reduction. FUNDING: Extended follow-up was funded under NIH contract HHSN261201600007I.
Authors: V Paul Doria-Rose; Pamela M Marcus; Anthony B Miller; Eric J Bergstralh; Jack S Mandel; Melvyn S Tockman; Philip C Prorok Journal: Clin Trials Date: 2010-02 Impact factor: 2.486
Authors: Brenda K Edwards; Elizabeth Ward; Betsy A Kohler; Christie Eheman; Ann G Zauber; Robert N Anderson; Ahmedin Jemal; Maria J Schymura; Iris Lansdorp-Vogelaar; Laura C Seeff; Marjolein van Ballegooijen; S Luuk Goede; Lynn A G Ries Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Timothy Church; Adeyinka O Laiyemo; Robert Bresalier; Gerald L Andriole; Saundra S Buys; E David Crawford; Mona N Fouad; Claudine Isaacs; Christine C Johnson; Douglas J Reding; Barbara O'Brien; Danielle M Carrick; Patrick Wright; Thomas L Riley; Mark P Purdue; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok; Christine D Berg Journal: N Engl J Med Date: 2012-05-21 Impact factor: 91.245
Authors: Joel L Weissfeld; Robert E Schoen; Paul F Pinsky; Robert S Bresalier; V Paul Doria-Rose; Adeyinka O Laiyemo; Timothy Church; Lance A Yokochi; Susan Yurgalevitch; Joshua Rathmell; Gerald L Andriole; Saundra Buys; E David Crawford; Mona Fouad; Claudine Isaacs; Lois Lamerato; Douglas Reding; Philip C Prorok; Christine D Berg Journal: J Natl Cancer Inst Date: 2012-01-31 Impact factor: 13.506
Authors: Philip Schoenfeld; Brooks Cash; Andrew Flood; Richard Dobhan; John Eastone; Walter Coyle; James W Kikendall; Hyungjin Myra Kim; David G Weiss; Theresa Emory; Arthur Schatzkin; David Lieberman Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Anna M Forsberg; Lars Kjellström; Lars Agréus; Anna Nixon Andreasson; Henry Nyhlin; Nicholas J Talley; Erik Björck Journal: Scand J Gastroenterol Date: 2012-01-10 Impact factor: 2.423
Authors: Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Ángel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernández; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono; José Cruzado; Francisco Pérez-Riquelme; Inmaculada Alonso-Abreu; Mariola de la Vega-Prieto; Juana Maria Reyes-Melian; Guillermo Cacho; José Díaz-Tasende; Alberto Herreros-de-Tejada; Carmen Poves; Cecilio Santander; Andrés González-Navarro Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: Rafael Cardoso; Feng Guo; Thomas Heisser; Harlinde De Schutter; Nancy Van Damme; Mef Christina Nilbert; Jane Christensen; Anne-Marie Bouvier; Véronique Bouvier; Guy Launoy; Anne-Sophie Woronoff; Mélanie Cariou; Michel Robaszkiewicz; Patricia Delafosse; Florence Poncet; Paul M Walsh; Carlo Senore; Stefano Rosso; Valery E P P Lemmens; Marloes A G Elferink; Sonja Tomšič; Tina Žagar; Arantza Lopez de Munain Marques; Rafael Marcos-Gragera; Montse Puigdemont; Jaume Galceran; Marià Carulla; Antonia Sánchez-Gil; María-Dolores Chirlaque; Michael Hoffmeister; Hermann Brenner Journal: Lancet Reg Health Eur Date: 2022-07-06
Authors: Kirles Bishay; Zhao Wu Meng; Levi Frehlich; Matthew T James; Gilaad G Kaplan; Michael J Bourke; Robert J Hilsden; Steven J Heitman; Nauzer Forbes Journal: Surg Endosc Date: 2021-03-09 Impact factor: 4.584
Authors: Maaike Buskermolen; Dayna R Cenin; Lise M Helsingen; Gordon Guyatt; Per Olav Vandvik; Ulrike Haug; Michael Bretthauer; Iris Lansdorp-Vogelaar Journal: BMJ Date: 2019-10-02
Authors: Henriette C Jodal; Lise M Helsingen; Joseph C Anderson; Lyubov Lytvyn; Per Olav Vandvik; Louise Emilsson Journal: BMJ Open Date: 2019-10-02 Impact factor: 2.692
Authors: Neel I Nissen; Stephanie Kehlet; Mogens K Boisen; Maria Liljefors; Christina Jensen; Astrid Z Johansen; Julia S Johansen; Janine T Erler; Morten Karsdal; Joachim H Mortensen; Anette Høye; Nicholas Willumsen Journal: Sci Rep Date: 2021-01-13 Impact factor: 4.379
Authors: Lise Mørkved Helsingen; Linan Zeng; Reed Alexander Siemieniuk; Lyubov Lytvyn; Per Olav Vandvik; Thomas Agoritsas; Michael Bretthauer; Gordon Guyatt Journal: BMJ Open Date: 2020-12-02 Impact factor: 2.692
Authors: Rafael Cardoso; Anna Zhu; Feng Guo; Thomas Heisser; Michael Hoffmeister; Hermann Brenner Journal: Dtsch Arztebl Int Date: 2021-04-23 Impact factor: 5.594